European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
复制标题
DOI：
10.3324/haematol.2020.276402
复制
发表时间：
2021-08-01
期刊：
影响因子：
10.1
通讯作者：
Boccadoro M
中科院分区：
文献类型：
--
作者：
Bruno B;Wäsch R;Engelhardt M;Gay F;Giaccone L;D'Agostino M;Rodríguez-Lobato LG;Danhof S;Gagelmann N;Kröger N;Popat R;Van de Donk NWCJ;Terpos E;Dimopoulos MA;Sonneveld P;Einsele H;Boccadoro M
嵌合抗原受体（CAR）T细胞（CAR-T）极大地改变了B细胞恶性肿瘤的治疗前景，为复发/难治性患者提供了潜在的治愈方法。急性淋巴细胞白血病和非霍奇金淋巴瘤患者的长期缓解促进了骨髓瘤的进一步发展。特别是，靶向B细胞成熟抗原（BCMA）的CAR-T已经在大量预治疗的患者中建立了非常有希望的结果。此外，靶向其他抗原（即，SLAMF 7和CD 44 v6）目前正在研究中。然而，目前这些自体疗法都没有获得批准，尽管研究的总体反应率很高，但长期结局、毒性、治疗耐药性和并发症管理等主要问题限制了它们的广泛使用。在这里，我们批判性地回顾了最重要的临床前和临床发现，CAR-T治疗骨髓瘤的最新进展，以及仍然无法治愈的疾病的生物学发现，这些发现将进一步提高复发/难治性患者的安全性和有效性，迫切需要新的治疗方案。
Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.
登录
查看更多内容
影响因子：
4.4
作者：
De Salort, Jose;Sintes, Jordi;Engel, Pablo
通讯作者：
Engel, Pablo
影响因子：
5.8
作者：
Ali, Sahra;Moreau, Alexandre;Pignatti, Francesco
通讯作者：
Pignatti, Francesco
SLAMF7对于通过MAC-1整合素对造血肿瘤细胞的吞噬作用至关重要。
影响因子：
64.8
作者：
Chen J;Zhong MC;Guo H;Davidson D;Mishel S;Lu Y;Rhee I;Pérez-Quintero LA;Zhang S;Cruz-Munoz ME;Wu N;Vinh DC;Sinha M;Calderon V;Lowell CA;Danska JS;Veillette A
通讯作者：
Veillette A
影响因子：
5.6
作者：
De Munter S;Ingels J;Goetgeluk G;Bonte S;Pille M;Weening K;Kerre T;Abken H;Vandekerckhove B
通讯作者：
Vandekerckhove B
影响因子：
11.4
作者：
García-Guerrero E;Götz R;Doose S;Sauer M;Rodríguez-Gil A;Nerreter T;Kortüm KM;Pérez-Simón JA;Einsele H;Hudecek M;Danhof S
通讯作者：
Danhof S